LifeMD announced an exclusive strategic collaboration with AT&T on September 15, 2026, providing eligible wireless and fiber customers with complimentary access to its virtual care platform. The partnership waives the $19 monthly membership fee, valued at $228 annually, for over 100 million eligible subscribers. Initial rollout covers 29 million customers across 11 states, including Arizona, Florida, and Texas, with a nationwide expansion planned for January 2027. LifeMD receives a fixed fee per lead, with further compensation terms to be negotiated. This strategic alliance expands LifeMD's customer base within the telehealth and virtual pharmacy industry.

LifeMD, Inc. entered into a strategic co-marketing collaboration with Antares Pharma, Inc., a subsidiary of Halozyme, Inc., to support a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection. The program, launching in July 2026, will be available in 37 states and will utilize the Company's telehealth and pharmacy services to evaluate and prescribe, dispense, and ship XYOSTED directly to patients' homes. The agreements have an initial term of three years with automatic one-year renewals. LifeMD, Inc. is a telehealth and pharmacy services provider in the healthcare industry.